Anonymous20 days ago
The 2025 AHA/ACC blood pressure guidelines — the first major revision since 2017 — push treatment targets toward 120 mmHg systolic, expand medication eligibility to an additional 26.8 million Americans including many younger adults, and introduce novel treatments like renal denervation and GLP-1 medications for hypertension. But the aggressive downward push has sparked fierce debate over overtreatment risks, the burden on primary care, and whether clinical trial evidence translates to real-world practice for elderly and lower-risk patients.